In the context of immune checkpoint inhibition, current biomarkers thought to predict response include high tumor mutational burden, mismatch repair deficiency (MMRd)/microsatellite instability, high CD8+ T cell density, and PD-L1 expression [3]. The gene discussed is CD274; the disease is neoplasm.